CL2011002814A1 - Formas cristalinas de n-(2,6-dimetil-4-morfolin-4-il-fenil)-3,3-dimetil-butiramida; composicion farmaceutica; proceso de preparacion de n-(2,6-dimetil-4-morfolin-4-il-fenil)-3,3-dimetil-butiramida; y uso en el tratamiento de esquizofrenia, trastornos convulsivos, depresivos y de espectro bipolar. - Google Patents

Formas cristalinas de n-(2,6-dimetil-4-morfolin-4-il-fenil)-3,3-dimetil-butiramida; composicion farmaceutica; proceso de preparacion de n-(2,6-dimetil-4-morfolin-4-il-fenil)-3,3-dimetil-butiramida; y uso en el tratamiento de esquizofrenia, trastornos convulsivos, depresivos y de espectro bipolar.

Info

Publication number: CL2011002814A1
Authority: CL; Chile
Prior art keywords: dimethyl; morpholin; phenyl; butyramide; depressive
Prior art date: 2009-05-11

Application number

CL2011002814A

Other languages

English (en)

Spanish (es)

Inventor

Svend Treppendahl

Karin Lopez De Diego Heidi Lilporp

Original Assignee

H Lundbeck As

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-05-11

Filing date

2011-11-10

Publication date

2012-04-13

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42237259&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2011002814(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2011-11-10 Application filed by H Lundbeck As filed Critical H Lundbeck As

2012-04-13 Publication of CL2011002814A1 publication Critical patent/CL2011002814A1/es

Links

OVEJXWFUXCATFY-UHFFFAOYSA-N n-(2,6-dimethyl-4-morpholin-4-ylphenyl)-3,3-dimethylbutanamide Chemical compound CC1=C(NC(=O)CC(C)(C)C)C(C)=CC(N2CCOCC2)=C1 OVEJXWFUXCATFY-UHFFFAOYSA-N 0.000 title abstract 3
230000003001 depressive effect Effects 0.000 title abstract 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
239000008194 pharmaceutical composition Substances 0.000 title abstract 2
201000000980 schizophrenia Diseases 0.000 title abstract 2
238000001228 spectrum Methods 0.000 title abstract 2
238000002360 preparation method Methods 0.000 title 1
206010010904 Convulsion Diseases 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/06—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals
- C07D295/073—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals with the ring nitrogen atoms and the substituents separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Neurology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Pharmacology & Pharmacy (AREA)
General Health & Medical Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Hospice & Palliative Care (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Cosmetics (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

CL2011002814A 2009-05-11 2011-11-10 Formas cristalinas de n-(2,6-dimetil-4-morfolin-4-il-fenil)-3,3-dimetil-butiramida; composicion farmaceutica; proceso de preparacion de n-(2,6-dimetil-4-morfolin-4-il-fenil)-3,3-dimetil-butiramida; y uso en el tratamiento de esquizofrenia, trastornos convulsivos, depresivos y de espectro bipolar. CL2011002814A1 (es)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
DKPA200900597		2009-05-11

Publications (1)

Publication Number	Publication Date
CL2011002814A1 true CL2011002814A1 (es)	2012-04-13

Family

ID=42237259

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CL2011002814A CL2011002814A1 (es)	2009-05-11	2011-11-10	Formas cristalinas de n-(2,6-dimetil-4-morfolin-4-il-fenil)-3,3-dimetil-butiramida; composicion farmaceutica; proceso de preparacion de n-(2,6-dimetil-4-morfolin-4-il-fenil)-3,3-dimetil-butiramida; y uso en el tratamiento de esquizofrenia, trastornos convulsivos, depresivos y de espectro bipolar.

Country Status (23)

Country	Link
EP (1)	EP2430008A2 (fr)
JP (1)	JP2012526152A (fr)
KR (1)	KR20120022934A (fr)
CN (1)	CN102459208A (fr)
AR (1)	AR076556A1 (fr)
AU (1)	AU2010246724B2 (fr)
BR (1)	BRPI1013930A2 (fr)
CA (1)	CA2761383A1 (fr)
CL (1)	CL2011002814A1 (fr)
CO (1)	CO6460741A2 (fr)
CR (1)	CR20110590A (fr)
DO (1)	DOP2011000351A (fr)
EA (1)	EA201171381A1 (fr)
GE (1)	GEP20146006B (fr)
IL (1)	IL216148A0 (fr)
MA (1)	MA33351B1 (fr)
MX (1)	MX2011011885A (fr)
NZ (1)	NZ596738A (fr)
SG (1)	SG175968A1 (fr)
TN (1)	TN2011000557A1 (fr)
TW (1)	TW201041857A (fr)
WO (1)	WO2010130260A2 (fr)
ZA (1)	ZA201108112B (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US12508239B2 (en)	2019-08-02	2025-12-30	H. Lundbeck A/S	Alcohol derivatives as Kv7 potassium channel openers for use in epilepsy or seizures

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TWI349666B (en) *	2004-03-12	2011-10-01	Lundbeck & Co As H	Substituted morpholine and thiomorpholine derivatives
NZ575652A (en) *	2006-08-23	2011-08-26	Valeant Pharmaceuticals Int	Derivatives of 4-(n-azacycloalkyl) anilides as potassium channel modulators
CN101790374A (zh) *	2007-08-01	2010-07-28	H.隆德贝克有限公司	Kcnq钾通道开放剂用于减轻多巴胺能系统受到干扰的障碍或病症的症状或治疗这种障碍或病症的用途

2010
- 2010-05-06 TW TW099114459A patent/TW201041857A/zh unknown
- 2010-05-10 AR ARP100101588A patent/AR076556A1/es unknown
- 2010-05-11 JP JP2012510116A patent/JP2012526152A/ja active Pending
- 2010-05-11 CN CN2010800321765A patent/CN102459208A/zh active Pending
- 2010-05-11 AU AU2010246724A patent/AU2010246724B2/en not_active Ceased
- 2010-05-11 CA CA2761383A patent/CA2761383A1/fr not_active Abandoned
- 2010-05-11 NZ NZ596738A patent/NZ596738A/xx not_active IP Right Cessation
- 2010-05-11 MX MX2011011885A patent/MX2011011885A/es not_active Application Discontinuation
- 2010-05-11 GE GEAP201012498A patent/GEP20146006B/en unknown
- 2010-05-11 EP EP10719726A patent/EP2430008A2/fr not_active Withdrawn
- 2010-05-11 KR KR1020117026958A patent/KR20120022934A/ko not_active Withdrawn
- 2010-05-11 BR BRPI1013930A patent/BRPI1013930A2/pt not_active IP Right Cessation
- 2010-05-11 SG SG2011082492A patent/SG175968A1/en unknown
- 2010-05-11 EA EA201171381A patent/EA201171381A1/ru unknown
- 2010-05-11 WO PCT/DK2010/050101 patent/WO2010130260A2/fr not_active Ceased
- 2010-05-11 MA MA34435A patent/MA33351B1/fr unknown
2011
- 2011-11-03 IL IL216148A patent/IL216148A0/en unknown
- 2011-11-04 ZA ZA2011/08112A patent/ZA201108112B/en unknown
- 2011-11-04 TN TNP2011000557A patent/TN2011000557A1/en unknown
- 2011-11-10 CL CL2011002814A patent/CL2011002814A1/es unknown
- 2011-11-11 DO DO2011000351A patent/DOP2011000351A/es unknown
- 2011-11-11 CO CO11153611A patent/CO6460741A2/es not_active Application Discontinuation
- 2011-11-11 CR CR20110590A patent/CR20110590A/es unknown

Also Published As

Publication number	Publication date
AR076556A1 (es)	2011-06-22
AU2010246724B2 (en)	2013-03-21
GEP20146006B (en)	2014-01-10
WO2010130260A3 (fr)	2011-06-16
CA2761383A1 (fr)	2010-11-18
WO2010130260A9 (fr)	2012-10-18
DOP2011000351A (es)	2012-01-31
SG175968A1 (en)	2011-12-29
CN102459208A (zh)	2012-05-16
MX2011011885A (es)	2011-12-06
ZA201108112B (en)	2013-01-30
AU2010246724A1 (en)	2011-12-08
TW201041857A (en)	2010-12-01
WO2010130260A2 (fr)	2010-11-18
MA33351B1 (fr)	2012-06-01
NZ596738A (en)	2013-04-26
IL216148A0 (en)	2012-01-31
EP2430008A2 (fr)	2012-03-21
KR20120022934A (ko)	2012-03-12
CR20110590A (es)	2012-02-22
EA201171381A1 (ru)	2012-05-30
BRPI1013930A2 (pt)	2019-09-24
JP2012526152A (ja)	2012-10-25
CO6460741A2 (es)	2012-06-15
TN2011000557A1 (en)	2013-05-24

Similar Documents

Publication	Publication Date	Title
UY34278A (es)	2013-04-05	Derivados novedosos de oxazina y su uso en el tratamiento de enfermedades
CL2008000434A1 (es)	2008-08-22	Compuestos derivados de 2-amino-oxazolinas; proceso de obtencion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como depresion, ansiedad, estres, trastorno bipolar, entre otros.
CL2013002125A1 (es)	2013-12-20	Compuestos derivados de imidazo[5,1-f][1,2,4]triazinas; composicion farmaceutica; y uso en el tratamiento del deterioro cognitivo asociado con esquizofrenia.
CL2008003593A1 (es)	2010-01-04	Compuestos derivados de isoxazolo-piridazina; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de trastornos cognitivos como el alzheimer
CL2015000942A1 (es)	2016-01-04	Compuestos de benceno sustituido.
CL2009000200A1 (es)	2010-09-10	Compuestos derivados de 2,7-naftiridinas-1-ona, mediadores de syk; composicion farmaceutica; y uso en el tratamiento de una enfermedad inflamatoria, respiratoria, proliferativa celular o autoinmune.
DOP2015000304A (es)	2016-02-29	Inhibidores cristalinos de bromodominios
CL2008001373A1 (es)	2008-11-21	Compuestos derivados de fenilamino-benceno sustituidos; metodo de preparacion; composicion farmaceutica; kit farmceuticos; y uso de dichos compuestos en el tratamiento del cancer.
PA8784001A1 (es)	2009-02-09	Oxazolidinonas sustituidas y su uso
CL2007002207A1 (es)	2008-02-01	Compuestos derivados de sulfonilaminas; composicion farmaceutica; y uso de los compuestos en el tratamiento del glaucoma.
CL2007002708A1 (es)	2008-04-04	Compuestos derivados de pirrolo[2,3-b]piridina; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, caquexia, trastornos inflamatorios, entre otros.
UY34545A (es)	2013-07-31	Novedosas dihidropirimidinoisoquinolinonas y composiciones farmacéuticas de las mismas para el tratamiento de trastornos inflamatorios.
CL2009000349A1 (es)	2010-02-19	Compuestos derivados de 4,5-dihidro-oxazol-2-ilamina; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer.
CL2012003427A1 (es)	2013-04-01	Compuestos derivados de 5-amino-3,6-dihidro-1h-pirazina-2-ona; y uso en el tratamiento de enfermedades tales como alzheimer, senilidad, demencia, entre otras.
CL2015003444A1 (es)	2016-07-15	Compuestos de 3,4 dihidroisoquinolin-2(1h)-ilo
CL2013001591A1 (es)	2013-12-27	Compuestos derivados de triazolopiridina; inhibidores de pde10a; proceso de obtencion; composicion farmaceutica; y uso en el tratamiento o profilaxis de trastornos psicoticos, esquizofrenia, ansiedad, entre otras enfermedades.
CL2008002689A1 (es)	2009-11-27	Compuestos derivados de heterociclo 1,4 piperidina sustituida; compuestos intermediarios; composicion farmaceutica; proceso de preparacion; y su uso en el tratamiento del alzheimer y esquizofrenia.
CL2011000116A1 (es)	2011-06-17	Compuestos derivados de imidazo[1,2-a]piridina; procedimiento de preparacion; composicion farmaceutica; compuestos intermediarios; y uso en el tratamiento del cancer.
CL2008001818A1 (es)	2009-03-06	Ácido {4,6-bis(dimetilamino)-2-(4-(4-(trifluorometil)benzamido)bencil)pirimidin-5-il}acético amorfo y sus formas cristalinas i y ii; proceso de preparación; composición farmacéutica; y uso en el tratamiento de enfermedades inflamatorias tales como asma, rinitis alérgica, crohn, entre otras.
CL2009000119A1 (es)	2010-03-05	Compuestos derivados de amino-bencimidazoles sustituidos; composicion farmaceutica; y su uso en el tratamiento del alzheimer.
CL2015002897A1 (es)	2016-06-03	Inhibidores de bace1
CL2012002540A1 (es)	2013-01-11	Hidrato de hidrocloruro de agomelatina; forma cristalina; metodo de preparacion; composicion farmaceutica ; y su uso para el tratamiento de trastornos del sueño, estrés, ansiedad, depresion mayor, enfermedades cardiovasculares, entre otras.
NI201000015A (es)	2011-03-23	Bromhidrato de bupropión y aplicaciones terapéuticas
CL2008002545A1 (es)	2009-10-23	Compuestos derivados de fenoxi-bencil-carbamoilo; composicion farmaceutica; procedimiento para preparar la composicion farmaceutica; y su uso en el tratamiento del dolor.
BR112015013675A2 (pt)	2017-07-11	composições compreendendo vortioxetina e donepezil